Decursin inhibits osteoclastogenesis by downregulating NFATc1 and blocking fusion of pre-osteoclasts

다국어 초록 (Multilingual Abstract)

<P><B>Abstract</B></P> <P>Bone sustains its structure through dynamic interaction between osteoblastic cells and osteoclastic cells. But imbalance may lead to osteoporosis caused by overactivated osteoclast cells that have bone-resorbing function. Recently, herbs have been researched as major sources of medicines in many countries. In vitro and in vivo anti-osteoclastogenic activity of <I>Angelica gigas</I> NAKAI have been reported, but the biological activity of decursin, its major component in osteoclast differentiation is still unknown. Therefore, in this study, we explored whether decursin could affect RANKL-mediated osteoclastogenesis. The results showed that decursin efficiently inhibited RANKL-activated osteoclast differentiation by inhibiting transcriptional and translational expression of NFATc1, a major factor in RANKL-mediated osteoclastogenesis. Furthermore, decursin decreased fusion and migration of pre-osteoclasts by downregulating mRNA expression levels of DC-STAMP and β3 integrin, respectively. In addition, decursin prevents lipopolysaccharide (LPS)-induced bone erosion in vivo. In summary, decursin could prevent osteoclastogenesis and inflammatory bone loss via blockage of NFATc1 activity and fusion and migration of pre-osteoclasts, and it could be developed as a potent phytochemical candidate for treating pathologies of bone diseases.</P> <P><B>Highlights</B></P> <P> <UL> <LI> Decursin inhibits osteoclastogenesis by blocking the expression of NFATc1. </LI> <LI> Decursin decreases the fusion and migration of pre-osteoclasts through down-regulated DC-STAMP and β3 integrin by reduced NFATc1. </LI> <LI> Decursin could provide benefits for the treatment of some kind of bone diseases in the clinical aspect. </LI> </UL> </P>